As India grapples with a rising cardiovascular disease burden alongside rapid digital health adoption, in this exclusive conversation, Prasad Maganti, CEO of vTitan, shares with Dr. Asawari Savant from Elets News Network (ENN) how next-generation cardiac monitoring solutions like vCardio can bridge gaps in early detection, continuity of care, and affordability, while aligning India’s innovation trajectory with global remote cardiac care trends. Edited excerpts.

How do you assess India’s cardiac monitoring landscape today in terms of market maturity, scalability, and growth potential, and how does it stack up against global innovation and adoption curves in remote cardiac care?

According to analyst reports, the global cardiac monitoring market is projected to grow from $669 million in 2024 to $1.71 billion by 2034, reflecting a compound annual growth rate (CAGR) of 7.8%. While specific Indian market data is unavailable, the rapid expansion of healthcare infrastructure in India suggests it will capture a significant share of this growing market. Although India currently lags behind global markets in the adoption of advanced cardiac care technologies, it is rapidly advancing. Indigenous solutions such as vCardio, offering competitive pricing and customised features aligned with local healthcare needs, are expected to play a key role in increasing awareness and accelerating market adoption.

What major shifts in clinical practice, preventive cardiology, and home-based chronic care management are accelerating the adoption of next-generation cardiac monitoring solutions like vCardio?

Preventive care is now at the forefront, with screening serving as a key component. Individuals are increasingly opting for preventive health visits, whether at hospitals or at home, facilitated by online booking of lab tests via cloud-based platforms. Cardiac care is following a similar trend. The home healthcare sector is expanding rapidly, with providers offering diverse services ranging from basic patient support to advanced clinical care, including real-time vital monitoring and home ICU setups for chronic or critical cases. These changes are creating opportunities for innovative, technology-powered solutions like vCardio, which connects patients, caregivers, and healthcare providers on a unified platform, enabling smooth collection, analysis, and reporting of clinical data through web and mobile applications to deliver efficient, coordinated care.

What role can technologies like vCardio play in strengthening early detection and continuous monitoring across the care continuum?

Cardiac Monitoring technologies like vCardio play a key enabler role across the care continuum in managing the cardiac health of populations at large. Screening of at-risk populations, such as Diabetes, Hypertension patients and Post-MI cohorts, leads to early interventions significantly reducing the burden on tertiary healthcare centres and accompanying costs on patients. In Step-down ICUs, pre- and post-surgery, continuous monitoring with real-time alerts for cardiac events will lead to faster and more effective clinical response, improving patient outcomes. At home, cardiac monitoring over longer periods of time, in post-hospital discharge or in chronic cases, provides clinical oversight and care assistance at a click away. 

As India pushes for affordable med-tech innovation, what pricing strategy and manufacturing blueprint is vTitan adopting to ensure vCardio remains accessible to consumers, primary care clinics, and hospitals at scale?

Affordable medical technology innovations depend on two key factors: reduced research and development (R&D) expenses and lower manufacturing costs. India’s strategic location enables cost-effective R&D without compromising technological expertise. 

Manufacturing costs are primarily driven by scale and access to local supply chains, which India offers through a high local component content, up to 85% in our products, giving us a strong supply chain advantage. As India grows as a major market and embraces domestic technology, it will naturally meet the demand for scale. Together, these elements will drive affordable pricing, improved after-sales support, and greater customer satisfaction.

What exclusive information can you share about vCardio’s future expansion plans, whether in terms of new features, global markets, or adjacent clinical applications?

vCardio is a single-lead cardiac monitor, and work is on to deliver five lead cardiac monitor with the same form factor and ease of use, which will open up diagnostic space as well. We will also be deepening the AI to categorise more cardiac events based on multi-lead capability. We are on course to obtain FDA/CE certifications, which will enable us to launch the product in the global market. We also have plans to integrate other monitoring parameters like SPO2, Temperature, etc., to make it a very comprehensive vital monitoring solution available at the patient’s doorstep.  

Also read: Your Next Healthcare Innovation Isn’t an App; It’s a Better Message

What kinds of industry partnerships will be most critical in accelerating vCardio’s scale-up and wider adoption?

A major market opportunity for vCardio lies in home health care, whether used for cardiology screening or long-term continuous monitoring of critically ill patients. The home health care market in India is expanding, and we are currently engaging with key service providers in this space, anticipating significant adoption of vCardio. Additionally, we aim to collaborate with local governments to improve cardiac care delivery at primary health centres in rural areas.

Like 1

Dislike

Be a part of Elets Collaborative Initiatives. Join Us for Upcoming Events and explore business opportunities. Like us on Facebook , connect with us on LinkedIn and follow us on Twitter , Instagram.

Disclaimer: The views and opinions expressed in this article are solely those of the author and do not necessarily reflect the official policy or views of any organisation. The content is intended for informational and educational purposes only and should not be construed as medical advice.

"Exciting news! Elets technomedia is now on WhatsApp Channels Subscribe today by clicking the link and stay updated with the latest insights!" Click here!